首页
/
/
/
FAK
/
Ifebemtinib
Ifebemtinib
{[allProObj[0].p_purity_real_show]}
货号：A1678539
同义名：
IN-10018; BI-853520
Ifebemtinib (BI 853520)是一种口服活性粘附斑激酶 (FAK) 抑制剂，对癌细胞具有抗增殖活性。
Ifebemtinib 化学结构
CAS号：1227948-82-4
Ifebemtinib 3D分子结构
CAS号：1227948-82-4
| 规格 |
价格 |
会员价
|
库存 |
数量 |
|
{[ item.pr_size ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}
{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]}
{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}
{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]}
{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
|
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]}
{[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]}
{[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}
|
现货 |
1周
咨询
|
-
+
|
Ifebemtinib 纯度/质量文件 产品仅供科研
货号：A1678539
标准纯度：
{[allProObj[0].p_purity_real_show]}
-
全球学术期刊中引用的产品
- • Nature, 2025, 645, 793-800. Ambeed.
[
A201204 ,
A444152 ,
A344107 ,
A952055
]
- • Cell, 2025. Ambeed.
[
A122167
]
- • Science, 2025, 387(6729): eadp5637. Ambeed.
[
A875019
]
- • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed.
[
A104916
]
- • Nat. Nanotechnol., 2025. Ambeed.
[
A243018 ,
A1216705 ,
A522597 ,
A125401 ,
A1355641
]
- 更多 >
Ifebemtinib 质控信息
Ifebemtinib 细胞实验
|
Cell Line
|
Concentration |
Treated Time |
Description |
References |
| PC-3 prostate carcinoma cells |
3 nmol/L |
|
blocks anchorage-independent proliferation |
Oncogenesis. 2018 Feb 23;7(2):21 |
| SPC111, SPC212, P31, and M38K cells |
0.1 μM and 1 μM |
96 hours |
To assess the effect of BI 853520 on spheroid formation, BI 853520 significantly reduced spheroid numbers |
J Mol Med (Berl). 2019 Feb;97(2):231-242 |
| SPC111, SPC212, P31, and M38K cells |
1 μM |
24 hours |
To evaluate the effect of BI 853520 on cell migration, BI 853520 showed anti-migratory effects in three out of four cell lines |
J Mol Med (Berl). 2019 Feb;97(2):231-242 |
| Py2T-LT cells |
1 µM |
24 hours |
BI 853520 significantly reduces Y397-FAK autophosphorylation. |
Oncogenesis. 2018 Sep 20;7(9):73 |
| Py2T cells |
1 µM |
24 hours |
BI 853520 significantly reduces Y397-FAK autophosphorylation. |
Oncogenesis. 2018 Sep 20;7(9):73 |
| 4T1 cells |
0.1 µM |
24 hours |
BI 853520 significantly reduces Y397-FAK autophosphorylation. |
Oncogenesis. 2018 Sep 20;7(9):73 |
| Calu-6 lung adenocarcinoma cells |
3 nmol/L |
|
inhibition of cell proliferation |
Oncogenesis. 2018 Feb 23;7(2):21 |
|
Ifebemtinib 动物实验
|
Species
|
Animal Model
|
Administration |
Dosage |
Frequency |
Description |
References |
| Mice |
Breast cancer models |
Oral |
50 mg/kg |
Once daily for 8 weeks |
BI 853520 significantly suppresses primary tumor growth and tumor progression. |
Oncogenesis. 2018 Sep 20;7(9):73 |
| Nude mice |
PC-3 prostate adenocarcinoma xenografts |
Oral |
50 mg/kg |
Once daily for 17 days |
Inhibition of tumor growth |
Oncogenesis. 2018 Feb 23;7(2):21 |
| SCID mice |
Orthotopic MPM xenograft model |
Oral |
20 mg/kg |
Five times a week for 3 weeks |
To evaluate the effect of BI 853520 on tumor growth, BI 853520 significantly reduced tumor load, tumor cell proliferation, and microvessel density |
J Mol Med (Berl). 2019 Feb;97(2):231-242 |
|
Ifebemtinib 实验方案
| 计算器 |
|
| 存储液制备 |
 |
1mg |
5mg |
10mg |
|
1 mM
5 mM
10 mM
|
1.70mL
0.34mL
0.17mL
|
8.50mL
1.70mL
0.85mL
|
16.99mL
3.40mL
1.70mL
|
Ifebemtinib 技术信息
搜索
